IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.817
AS - Asia 2.374
EU - Europa 1.732
SA - Sud America 326
AF - Africa 170
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 2
Totale 7.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.724
SG - Singapore 850
CN - Cina 595
VN - Vietnam 436
IT - Italia 332
SE - Svezia 300
IE - Irlanda 290
BR - Brasile 237
DE - Germania 181
HK - Hong Kong 178
FR - Francia 137
ZA - Sudafrica 107
FI - Finlandia 83
TR - Turchia 83
NL - Olanda 82
GB - Regno Unito 66
AT - Austria 62
CA - Canada 62
RU - Federazione Russa 42
IN - India 41
AR - Argentina 31
BD - Bangladesh 30
CZ - Repubblica Ceca 22
JP - Giappone 22
RO - Romania 22
IQ - Iraq 20
BE - Belgio 19
CI - Costa d'Avorio 18
PL - Polonia 18
ES - Italia 17
MX - Messico 16
TH - Thailandia 16
UA - Ucraina 14
PK - Pakistan 13
ID - Indonesia 12
PH - Filippine 12
VE - Venezuela 12
LT - Lituania 11
CL - Cile 10
EC - Ecuador 10
PY - Paraguay 10
CO - Colombia 9
KR - Corea 9
KE - Kenya 8
MA - Marocco 8
AE - Emirati Arabi Uniti 6
ET - Etiopia 6
EU - Europa 6
UZ - Uzbekistan 6
BG - Bulgaria 5
EG - Egitto 5
IL - Israele 5
TW - Taiwan 5
CR - Costa Rica 4
KH - Cambogia 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
IR - Iran 3
JO - Giordania 3
KZ - Kazakistan 3
LU - Lussemburgo 3
LV - Lettonia 3
MD - Moldavia 3
NG - Nigeria 3
OM - Oman 3
PE - Perù 3
QA - Qatar 3
RS - Serbia 3
SC - Seychelles 3
TN - Tunisia 3
DK - Danimarca 2
HN - Honduras 2
JM - Giamaica 2
MU - Mauritius 2
MZ - Mozambico 2
NP - Nepal 2
PT - Portogallo 2
SM - San Marino 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
KI - Kiribati 1
KW - Kuwait 1
LB - Libano 1
Totale 7.418
Salva come PNG Salva come JPEG
Città #
Singapore 458
Ashburn 418
Chandler 333
Dublin 286
San Jose 226
Santa Clara 186
Hong Kong 171
Dallas 157
Ho Chi Minh City 136
Parma 133
Beijing 119
Johannesburg 102
Hanoi 99
Ann Arbor 93
Shanghai 92
New York 90
Boardman 85
Los Angeles 85
Dearborn 67
Munich 62
Vienna 57
Izmir 54
Lauterbourg 52
Nanjing 51
Princeton 45
Marseille 38
São Paulo 31
Helsinki 28
Wilmington 27
Columbus 25
The Dalles 24
Toronto 24
Bremen 23
Buffalo 23
Moscow 23
Shenyang 23
Turku 22
Council Bluffs 21
Orem 21
Tokyo 20
Da Nang 19
Abidjan 18
Brno 18
Brussels 18
Milan 17
Warsaw 16
Houston 15
Poplar 15
San Mateo 15
Frankfurt am Main 14
Hebei 14
Jinan 14
Kunming 14
Düsseldorf 13
Hefei 13
Nanchang 13
Haiphong 12
Kocaeli 12
London 12
Montreal 12
Amsterdam 11
Atlanta 11
Modena 11
Nuremberg 11
Rome 11
Stockholm 11
Ankara 10
Biên Hòa 10
Chennai 10
Denver 10
Focsani 10
Guangzhou 10
Jakarta 10
Redmond 10
Brooklyn 9
Bangkok 8
Bologna 8
Changsha 8
Dhaka 8
Fairfield 8
Jiaxing 8
Ottawa 8
Woodbridge 8
Chicago 7
Hải Dương 7
Manchester 7
Norwalk 7
Pune 7
San Francisco 7
Tianjin 7
Zhengzhou 7
Addis Ababa 6
Asunción 6
Boston 6
Can Tho 6
Jacksonville 6
Madrid 6
Nairobi 6
Phoenix 6
Rio de Janeiro 6
Totale 4.653
Salva come PNG Salva come JPEG
Nome #
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 212
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 210
A simplified sars-cov-2 pseudovirus neutralization assay 208
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 203
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 195
Novel targets for the treatment of relapsing multiple myeloma 189
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 189
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 187
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 178
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 178
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 172
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 172
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 166
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 162
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 161
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 157
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 157
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 156
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 156
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 155
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 155
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 153
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 152
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 151
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 150
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 147
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 147
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 146
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 146
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 145
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 144
The impact of CD56 expression in smoldering myeloma patients on early progression 134
Oncolytic virotherapy and microenvironment in multiple myeloma 134
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 133
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 133
Possible targets to treat myeloma-related osteoclastogenesis 131
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 128
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 126
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 124
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 109
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 109
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 107
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 104
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 103
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 101
Role of Galectins in Multiple Myeloma. 100
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 99
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 96
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 95
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 94
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 89
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 89
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes 12
Totale 7.549
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.983
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.983
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 0 0 0 0 28 16 29
2021/2022296 6 10 10 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/20251.531 27 60 84 140 162 142 106 87 194 119 144 266
2025/20262.999 318 244 362 301 469 201 341 111 400 252 0 0
Totale 7.549